NASDAQ: AIXCAixcrypto Holdings Inc Stock
$1.30+0.01 (+0.78%)
Updated Jun 11, 2026
AIXC Price
$1.30
Fair Value Price
N/A
Market Cap
$26.31M
52 Week Low
$0.94
52 Week High
$8.81
P/E
-0.13x
P/B
1.2x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.40M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$10M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AIXC Overview
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AIXC's potential to beat the market
- AIXC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AIXC
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important AIXC news, forecast changes, insider trades & much more!
AIXC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AIXC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AIXC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AIXC is good value based on its book value relative to its share price (1.2x), compared to the US Biotechnology industry average (4.83x)
P/B vs Industry Valuation
AIXC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more AIXC due diligence checks available for Premium users.
Valuation
AIXC fair value
Fair Value of AIXC stock based on Discounted Cash Flow (DCF)
Price
$1.30
Fair Value
$3.25
Undervalued by
59.98%
AIXC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AIXC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.13x
Industry
17.66x
Market
13.95x
AIXC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.2x
Industry
4.83x
AIXC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AIXC's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.1M
Profit Margin
0%
AIXC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$23.9M
Liabilities
$2.0M
Debt to equity
0.09
AIXC's short-term assets ($23.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIXC's short-term assets ($23.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIXC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AIXC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5M
Investing
-$8.5M
Financing
-$132.0k
AIXC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AIXC vs Biotech Stocks
Aixcrypto Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.